World Heart Pump Study Halted For FDA Refinement Review
09 Février 2011 - 4:03PM
Dow Jones News
World Heart Corp. (WHRT) has paused enrollment in a study of its
Levacor heart pump, pending regulatory approval of refinements to
the device.
The pump uses magnetic levitation to suspend the spinning
impeller, its only moving part, where others use blood or
mechanical bearings. The company says that's expected to provide
improved blood compatibility. World Heart has been unprofitable as
it is focused on development of the device.
The company said Wednesday design modifications will be
"technically ready in the next two to three months," but the
timeline for their implementation depends on approval by the U.S.
Food and Drug Administration, the timing of which is uncertain.
Shares closed Tuesday at $1.86 and were halted premarket on the
news.
-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com
World Heart (NASDAQ:WHRT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
World Heart (NASDAQ:WHRT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about World Heart Corp. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur World Heart Corp.